Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 83 entries
Sorted by: Best Match Show Resources per page
Assessment of second-line treatments for patients with uncontrolled moderate asthma.

International journal of clinical and experimental medicine

Wang K, Tian P, Fan Y, Wang Y, Liu C.
PMID: 26770595
Int J Clin Exp Med. 2015 Oct 15;8(10):19476-80. eCollection 2015.

AIM: To evaluate the best second-line treatments for patients with uncontrolled moderate asthma.METHODS: A single-center, random study was conducted in adult patients with uncontrolled moderate asthma to evaluate the effects of add-on treatments. After add-on treatments for 4 and...

Cite
Wang K, Tian P, Fan Y, et al. Assessment of second-line treatments for patients with uncontrolled moderate asthma. Int J Clin Exp Med. 2015;8(10):19476-80
Wang, K., Tian, P., Fan, Y., Wang, Y., & Liu, C. (2015). Assessment of second-line treatments for patients with uncontrolled moderate asthma. International journal of clinical and experimental medicine, 8(10), 19476-80.
Wang, Ke, et al. "Assessment of second-line treatments for patients with uncontrolled moderate asthma." International journal of clinical and experimental medicine vol. 8,10 (2015): 19476-80.
Wang K, Tian P, Fan Y, Wang Y, Liu C. Assessment of second-line treatments for patients with uncontrolled moderate asthma. Int J Clin Exp Med. 2015 Oct 15;8(10):19476-80. eCollection 2015. PMID: 26770595; PMCID: PMC4694495.
Copy Download .nbib Format: NLM
Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease: A randomized comparative trial.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Panahi Y, Ghanei M, Behzadi M, Salehi M, Soflaei SS, Sahebkar A.
PMID: 27013907
Saudi Pharm J. 2016 Mar;24(2):147-52. doi: 10.1016/j.jsps.2015.01.005. Epub 2015 Jan 12.

INTRODUCTION: The beneficial effects of tiotropium bromide, a long acting anticholinergic bronchodilator, in the management of chronic obstructive pulmonary disease have been shown in previous studies. The present study aimed to compare the efficacy and safety of generic (Tiova®)...

Cite
Panahi Y, Ghanei M, Behzadi M, et al. Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease: A randomized comparative trial. Saudi Pharm J. 2015;24(2):147-52doi: 10.1016/j.jsps.2015.01.005.
Panahi, Y., Ghanei, M., Behzadi, M., Salehi, M., Soflaei, S. S., & Sahebkar, A. (2016). Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease: A randomized comparative trial. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 24(2), 147-52. https://doi.org/10.1016/j.jsps.2015.01.005
Panahi, Yunes, et al. "Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease: A randomized comparative trial." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 24,2 (2016): 147-52. doi: https://doi.org/10.1016/j.jsps.2015.01.005
Panahi Y, Ghanei M, Behzadi M, Salehi M, Soflaei SS, Sahebkar A. Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease: A randomized comparative trial. Saudi Pharm J. 2016 Mar;24(2):147-52. doi: 10.1016/j.jsps.2015.01.005. Epub 2015 Jan 12. PMID: 27013907; PMCID: PMC4792902.
Copy Download .nbib Format: NLM
Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study.

Multidisciplinary respiratory medicine

Dal Negro RW, Longo P, Ziani OV, Bonadiman L, Turco P.
PMID: 28560037
Multidiscip Respir Med. 2017 May 29;12:13. doi: 10.1186/s40248-017-0096-1. eCollection 2017.

BACKGROUND: Inhalation is the preferred route for respiratory drug delivery, but several factors contribute to the variability of the respirable dose fraction. Instant velocity and the dynamic characteristics of the droplet cloud represent crucial factors. Aim was to measure...

Cite
Dal Negro RW, Longo P, Ziani OV, et al. Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study. Multidiscip Respir Med. 2017;12:13doi: 10.1186/s40248-017-0096-1.
Dal Negro, R. W., Longo, P., Ziani, O. V., Bonadiman, L., & Turco, P. (2017). Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study. Multidisciplinary respiratory medicine, 1213. https://doi.org/10.1186/s40248-017-0096-1
Dal Negro, Roberto W, et al. "Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study." Multidisciplinary respiratory medicine vol. 12 (2017): 13. doi: https://doi.org/10.1186/s40248-017-0096-1
Dal Negro RW, Longo P, Ziani OV, Bonadiman L, Turco P. Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study. Multidiscip Respir Med. 2017 May 29;12:13. doi: 10.1186/s40248-017-0096-1. eCollection 2017. PMID: 28560037; PMCID: PMC5447303.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 16082422
Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(5):331-72
Bayés, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(5), 331-72.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,5 (2005): 331-72.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PMID: 16082422.
Copy Download .nbib Format: NLM
Gateways to clinical trials. July-August 2008.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 18850047
Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95.

(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept, Aliskiren fumarate, Apixaban, Atazanavir sulfate, Atrasentan, Axitinib; BI-1744-CL, BIBF-1120, BIBW-2992, Bortezomib; Carboxyamidotriazole, Caspofungin acetate, CBP-501, Cediranib, Ceftobiprole, Certolizumab pegol, Cetuximab, Cholesteryl hydrophobized polysaccharide-Her2 protein complex, CHP-NY-ESO-1, Cypher;...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008;30(6):459-95
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. July-August 2008. Methods and findings in experimental and clinical pharmacology, 30(6), 459-95.
Tomillero, A, and Moral, M A. "Gateways to clinical trials. July-August 2008." Methods and findings in experimental and clinical pharmacology vol. 30,6 (2008): 459-95.
Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PMID: 18850047.
Copy Download .nbib Format: NLM
Retraction: Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease patients: comparison with oxitropium bromide.

Internal medicine (Tokyo, Japan)

Matsuyama W, Mitsuyama H, Koreeda Y, Higashimoto I, Osame M, Arimura K.
PMID: 18825845
Intern Med. 2008;47(14):1371. doi: 10.2169/internalmedicine.47.r001.

No abstract available.

Cite
Matsuyama W, Mitsuyama H, Koreeda Y, et al. Retraction: Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease patients: comparison with oxitropium bromide. Intern Med. 2008;47(14):1371doi: 10.2169/internalmedicine.47.r001.
Matsuyama, W., Mitsuyama, H., Koreeda, Y., Higashimoto, I., Osame, M., & Arimura, K. (2008). Retraction: Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease patients: comparison with oxitropium bromide. Internal medicine (Tokyo, Japan), 47(14), 1371. https://doi.org/10.2169/internalmedicine.47.r001
Matsuyama, Wataru, et al. "Retraction: Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease patients: comparison with oxitropium bromide." Internal medicine (Tokyo, Japan) vol. 47,14 (2008): 1371. doi: https://doi.org/10.2169/internalmedicine.47.r001
Matsuyama W, Mitsuyama H, Koreeda Y, Higashimoto I, Osame M, Arimura K. Retraction: Use of tiotropium bromide for pre-operative treatment in chronic obstructive pulmonary disease patients: comparison with oxitropium bromide. Intern Med. 2008;47(14):1371. doi: 10.2169/internalmedicine.47.r001. PMID: 18825845.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 20508873
Methods Find Exp Clin Pharmacol. 2010 May;32(4):247-88. doi: 10.1358/mf.2010.32.4.1507200.

O(6)-Benzylguanine; (-)-Gossypol; Abatacept, AC-2592, Adalimumab, AIDSVAX gp120 B/E, Alemtuzumab, Aliskiren fumarate, ALVAC E120TMG, Ambrisentan, Amlodipine, Anakinra, Aripiprazole, Armodafinil, Atomoxetine hydrochloride, Avotermin; Bevacizumab, BIBW-2992, Bortezomib, Bosentan, Botulinum toxin type B; Canakinumab, CAT-354, Ciclesonide, CMV gB vaccine, Corifollitropin alfa, Daptomycin, Darbepoetin...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010;32(4):247-88doi: 10.1358/mf.2010.32.4.1507200.
Tomillero, A., & Moral, M. A. (2010). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 32(4), 247-88. https://doi.org/10.1358/mf.2010.32.4.1507200
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 32,4 (2010): 247-88. doi: https://doi.org/10.1358/mf.2010.32.4.1507200
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 May;32(4):247-88. doi: 10.1358/mf.2010.32.4.1507200. PMID: 20508873.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 18040531
Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83.

(-)-Epigallocatechin gallate, [188Re]-P2045, 12B75, 89-12; Abacavir sulfate/lamivudine, Abatacept, Abiraterone acetate, ABT-869, Adalimumab, Ad-rh Endostatin, AI-700, Alemtuzumab, Alvimopan hydrate, Amrubicin hydrochloride, AP-12009, Apomab 7.3, Arformoterol tartrate, Aripiprazole, AS-1404, Azacitidine, AZD-0530; Bevacizumab, BHT-3009, Biapenem, Bortezomib, Bosentan, Bremelanotide; CA9-SCAN, Calcitonin gene-related peptide,...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007;29(8):547-83
Bayes, M., Rabasseda, X., & Prous, J. R. (2007). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 29(8), 547-83.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 29,8 (2007): 547-83.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PMID: 18040531.
Copy Download .nbib Format: NLM
The role of tiotropium in the management of asthma.

Asia Pacific allergy

Park HW.
PMID: 22701860
Asia Pac Allergy. 2012 Apr;2(2):109-14. doi: 10.5415/apallergy.2012.2.2.109. Epub 2012 Apr 30.

Asthma is a chronic respiratory disease characterized by reversible airway obstruction that is secondary to an allergic inflammation and excessive smooth muscle contraction. Cholinergic signals were known to contribute significantly to the pathophysiology of asthma. However, the use of...

Cite
Park HW. The role of tiotropium in the management of asthma. Asia Pac Allergy. 2012;2(2):109-14doi: 10.5415/apallergy.2012.2.2.109.
Park, H. W. (2012). The role of tiotropium in the management of asthma. Asia Pacific allergy, 2(2), 109-14. https://doi.org/10.5415/apallergy.2012.2.2.109
Park, Heung-Woo. "The role of tiotropium in the management of asthma." Asia Pacific allergy vol. 2,2 (2012): 109-14. doi: https://doi.org/10.5415/apallergy.2012.2.2.109
Park HW. The role of tiotropium in the management of asthma. Asia Pac Allergy. 2012 Apr;2(2):109-14. doi: 10.5415/apallergy.2012.2.2.109. Epub 2012 Apr 30. PMID: 22701860; PMCID: PMC3345323.
Copy Download .nbib Format: NLM
The role of indacaterol for chronic obstructive pulmonary disease (COPD).

Journal of thoracic disease

Cazzola M, Bardaro F, Stirpe E.
PMID: 23991316
J Thorac Dis. 2013 Aug;5(4):559-66. doi: 10.3978/j.issn.2072-1439.2013.07.35.

Indacaterol is the first long-acting β2-agonist (LABAs) approved for the treatment of chronic obstructive pulmonary disease (COPD) that allows for once-daily (OD) administration. It is rapidly acting, with an onset of action in 5 minutes, like salbutamol and formoterol...

Cite
Cazzola M, Bardaro F, Stirpe E. The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis. 2013;5(4):559-66doi: 10.3978/j.issn.2072-1439.2013.07.35.
Cazzola, M., Bardaro, F., & Stirpe, E. (2013). The role of indacaterol for chronic obstructive pulmonary disease (COPD). Journal of thoracic disease, 5(4), 559-66. https://doi.org/10.3978/j.issn.2072-1439.2013.07.35
Cazzola, Mario, et al. "The role of indacaterol for chronic obstructive pulmonary disease (COPD)." Journal of thoracic disease vol. 5,4 (2013): 559-66. doi: https://doi.org/10.3978/j.issn.2072-1439.2013.07.35
Cazzola M, Bardaro F, Stirpe E. The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis. 2013 Aug;5(4):559-66. doi: 10.3978/j.issn.2072-1439.2013.07.35. PMID: 23991316; PMCID: PMC3755680.
Copy Download .nbib Format: NLM
Tiotropium in asthma: back to the future of anticholinergic treatment.

Clinical and molecular allergy : CMA

Bonini M, Scichilone N.
PMID: 29213218
Clin Mol Allergy. 2017 Dec 04;15:20. doi: 10.1186/s12948-017-0076-1. eCollection 2017.

Asthma is among the most common chronic diseases worldwide; however, despite progresses in the understanding of the patho-physiological mechanisms and advances in the development of new therapeutic options and strategies, the disease remains uncontrolled in a not trivial proportion...

Cite
Bonini M, Scichilone N. Tiotropium in asthma: back to the future of anticholinergic treatment. Clin Mol Allergy. 2017;15:20doi: 10.1186/s12948-017-0076-1.
Bonini, M., & Scichilone, N. (2017). Tiotropium in asthma: back to the future of anticholinergic treatment. Clinical and molecular allergy : CMA, 1520. https://doi.org/10.1186/s12948-017-0076-1
Bonini, Matteo, and Scichilone, Nicola. "Tiotropium in asthma: back to the future of anticholinergic treatment." Clinical and molecular allergy : CMA vol. 15 (2017): 20. doi: https://doi.org/10.1186/s12948-017-0076-1
Bonini M, Scichilone N. Tiotropium in asthma: back to the future of anticholinergic treatment. Clin Mol Allergy. 2017 Dec 04;15:20. doi: 10.1186/s12948-017-0076-1. eCollection 2017. PMID: 29213218; PMCID: PMC5713051.
Copy Download .nbib Format: NLM
Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease.

Computational and mathematical methods in medicine

Yu S, Zhang C, Yan Z, Fang Q, Gao X.
PMID: 34650619
Comput Math Methods Med. 2021 Oct 05;2021:1341644. doi: 10.1155/2021/1341644. eCollection 2021.

BACKGROUND: Patients with stable chronic obstructive pulmonary disease (COPD) have been observed to benefit from tiotropium bromide. However, there are few studies of tiotropium bromide on sputum and sputum viscosity. To evaluate the effect of tiotropium bromide on mucus...

Cite
Yu S, Zhang C, Yan Z, et al. Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease. Comput Math Methods Med. 2021;2021:1341644doi: 10.1155/2021/1341644.
Yu, S., Zhang, C., Yan, Z., Fang, Q., & Gao, X. (2021). Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease. Computational and mathematical methods in medicine, 20211341644. https://doi.org/10.1155/2021/1341644
Yu, Suyun, et al. "Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease." Computational and mathematical methods in medicine vol. 2021 (2021): 1341644. doi: https://doi.org/10.1155/2021/1341644
Yu S, Zhang C, Yan Z, Fang Q, Gao X. Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease. Comput Math Methods Med. 2021 Oct 05;2021:1341644. doi: 10.1155/2021/1341644. eCollection 2021. PMID: 34650619; PMCID: PMC8510842.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 83 entries